Background
==========

Inflammatory bowel disease (IBD) is a group of chronic inflammatory diseases of the gastrointestinal tract with no specific etiology, and it includes ulcerative colitis and Crohn's disease, and other chronic, nonspecial inflammatory diseases of the gut with unknown etiology. The diagnosis is based on clinical, radiological, endoscopic, and histopathological studies. Several attempts have been made to uncover a possible infectious agent as a cause of IBD. But to date, such efforts have failed to prove any suspected pathogen.

Even though the etiology of IBD is unknown, recent studies have shown that the pathogenesis of IBD is related to susceptible genes, immune dysregulation, and microbiota of the gut.[@b1-idr-10-511] IBD is characterized by alternating phases of exacerbation and remission, and cytomegalovirus (CMV) infection is one prominent cause of exacerbation. In addition, CMV infection is an emerging and controversial complication in patients with IBD.[@b2-idr-10-511] There are many case reports which suggest that IBD patients are particularly vulnerable to CMV infection.

CMV is a β herpes virus with double-stranded DNA. Worldwide, the current infective rate ranges between 40% and 100%. CMV infection is a type of opportunistic infection, as the virus is reactivated and results in active CMV infection with characteristics of viremia and visceral injury (for example pneumonia or colitis) in immunocompromised patients. During the past few decades, abundant observational research has produced data on CMV prevalence in patients with IBD.[@b3-idr-10-511] Accordingly, previous studies recommended that CMV infection be suspected in IBD patients with resistance to steroid treatment.[@b4-idr-10-511] However, it is still uncertain whether CMV infection has an active role in IBD or whether it exists coincidentally.

The prevalence of CMV can be assessed in several ways. Serological CMV IgG testing provides data about latent infection, while IgM testing provides information on recent infection or, as is more likely in adults, reactivation. Other techniques used to demonstrate the virus include immunohistochemistry with antibodies to CMV early antigen or pp65, in situ hybridization to detect CMV mRNA, and polymerase chain reaction (PCR) for CMV DNA,[@b5-idr-10-511],[@b6-idr-10-511] and each has been used to attempt to quantify the infection.

The aims of this study were to clarify the association between CMV infection and IBD and to identify the relationship between CMV infection and steroid-resistant IBD.

Study design
============

Search strategy
---------------

We searched PubMed and Embase and for eligible studies to include in the present meta-analysis, using the terms "human cytomegalovirus" and "inflammation bowel disease" or "Crohn's disease" or "ulcerative colitis." An upper date limit of June 10, 2017 was applied; we used no lower date limit. Papers published in English were included. We reviewed citations in the retrieved papers to search for additional relevant studies. The retrieved studies were then read in their entirety to assess their appropriateness for the inclusion in this meta-analysis.

Inclusion/exclusion criteria
----------------------------

Studies were eligible for inclusion if they 1) evaluated the association between human cytomegalovirus (HCMV) infection and IBD; 2) evaluated the association between HCMV infection and steroid-resistant IBD; 3) were case--control studies or nested case--control studies; 4) and provided the numbers (or percentage) of positivity for HCMV infection in cases and controls, respectively. Conference abstracts, case reports, editorials, review articles, and letters were excluded.

Search selection and data extraction
------------------------------------

Two authors (Ya-li Lv and Fei-fei Han) extracted data and reached a consensus on all of the eligibility items according to the aforementioned inclusion criteria. The following data were collected from each study: first author's surname, the year of publication, source of cases, HCMV detection method, total numbers of cases and controls, and the positivity for HCMV infection in cases and controls or the incidence of steroid resistance in HCMV positive and negative patients, respectively.

All articles reporting data for HCMV prevalence based on enzyme-linked immunosorbent, PCR detection methods, and immunohistochemistry with antibodies to CMV early antigen or pp65 since April 12, 1975, were selected.

Statistical analysis
--------------------

All statistical analyses were performed using Review Manager (Review Manager 5.0 software; Cochrane, London, England, UK) and Stata/MP 11.0. Cochran's *w*^2^ test and the inconsistency index (*I*^2^) were used to evaluate heterogeneity across the included studies. Random-effects model was applied in all the analysis. Odds ratio (OR) and corresponding 95% confidence intervals (CIs) were estimated. Z-test was performed to determine the statistical significance of pooled OR, and was considered significant when *P*\<0.05. Statistical heterogeneity test was performed by using the χ^2^ and *I*^2^ statistics, and *I*^2^ value of more than 50% was considered as substantial heterogeneity.[@b7-idr-10-511]

Results
=======

Search results
--------------

Our search identified 705 potentially relevant studies, 30 of which met the predefined study criteria and were included in our meta-analysis. [Figure 1](#f1-idr-10-511){ref-type="fig"} summarizes the process of study identification, inclusion, and exclusion. There were 245 abstracts from the PubMed search and 460 articles from Embase search. After duplicates were removed, 667 records were assessed for eligibility, and 30 records were finally included in the analysis.[@b1-idr-10-511],[@b3-idr-10-511],[@b8-idr-10-511]--[@b35-idr-10-511]

Characteristics of included studies
-----------------------------------

The characteristics of included studies and patients are presented in [Table 1](#t1-idr-10-511){ref-type="table"}, including 18 studies, and [Table 2](#t2-idr-10-511){ref-type="table"} including 17 researches; there were 5 duplicates studies among these, so 30 records were included in the final analysis. [Table 1](#t1-idr-10-511){ref-type="table"} shows the characteristics and variables collected for the prevalence of CMV infection in IBD disease. And [Table 2](#t2-idr-10-511){ref-type="table"} displays the characteristics of the relationship between CMV infection and steroid-resistant IBD.

As shown in [Table 1](#t1-idr-10-511){ref-type="table"}, data were available for a total of 1,168 patients and 951 healthy people; containing 14 studies from a Caucasian subgroup, 2 from an Asian subgroup, and 1 from a subgroup of other ethnicities. As can be seen in [Table 2](#t2-idr-10-511){ref-type="table"}, data were available for a total of 1,306 patients, containing 11 studies from a Caucasian subgroup, 4 from an Asian subgroup, and 2 from a subgroup of other ethnicities.

Risk of CMV infection in patients with IBD
------------------------------------------

### Meta-analysis results

A meta-analysis of 18 studies is reported in [Table 1](#t1-idr-10-511){ref-type="table"} and [Figures 2](#f2-idr-10-511){ref-type="fig"}[](#f3-idr-10-511){ref-type="fig"}[](#f4-idr-10-511){ref-type="fig"}[](#f5-idr-10-511){ref-type="fig"}--[6](#f6-idr-10-511){ref-type="fig"}, dealing with the association between HCMV infection and IBD disease. When involving 18 studies including 1,168 patients and 951 health groups, a total HCMV positive ratio of 69.6% in IBD patients (247/352) and 51.82% in control groups (171/330) based HCMV IgG tests, 5.5% in IBD patients (18/325) and 0.59% in control groups (28/895) based HCMV IgM tests, 42.5% in IBD patients (351/826) and 26.4% in control groups (201/762) based HCMV DNA tests, 48.8% in IBD patients (79/162) and 10.3% in control groups (12/116) based on HCMV immediate-early (IE) tests, and 40.4% in IBD patients (92/228) and 6.6% in control groups (8/121) based on HCMV pp65 tests was observed.

Compared with the control groups, people exposed to HCMV infection had higher risk than those not exposed to CMV. The ORs of HCMV infection rate in IBD patients compared to the control groups were, respectively, 7.14 \[95% CI =1.58--32.25, *p*=0.01\] based on HCMV IgM tests, 4.99 \[95% CI =2.40--10.40, *p*\<0.0001\] based on HCMV DNA tests, 8.43 \[95% CI =4.08--17.42, *p*\<0.00001\] based on HCMV IE tests, and 7.44 \[95% CI =3.12--17.76, *p*\<0.00001\] based on HCMV pp65 tests. However, there was no difference in the risk of HCMV infection rate in IBD patients compared to the control groups based on HCMV IgG tests \[OR =1.36, 95% CI =0.45--4.14, *p*=0.59\].

### Subgroup analysis

In the stratified analysis by ethnicity, through the experimental results ([Figure 4](#f4-idr-10-511){ref-type="fig"}), HCMV infection was distinctly confirmed as a risk factor for the occurrence and development of IBD in Asian and Caucasian groups based on HCMV DNA tests, with ORs of 7.46 \[95% CI =1.58--35.34, *p*=0.01\] and 4.51 \[95% CI =1.68--12.10, *p*=0.003\], respectively.

Risk of CMV infection in patients with steroid-resistant IBD
------------------------------------------------------------

### Meta-analysis results

When involving 17 studies including 1,306 IBD patients, a total of 52.9% of patients in the CMV-positive groups were observed to have steroid resistance, compared with 30.2% of patients in the CMV-negative groups. There was a significant difference in the risk of steroid resistance between people exposed to HCMV infection and those not exposed HCMV infection for IBD patients \[OR =3.63, 95% CI =1.99--6.62, *p*\<0.0001\].

### Subgroup analysis

In the stratified analysis by ethnicity and CMV detection method, HCMV infection was distinctly confirmed as a risk factor for the occurrence of steroid-resistant IBD through the experimental results ([Table 3](#t3-idr-10-511){ref-type="table"}).

Sensitivity analysis
--------------------

The purpose of sensitivity analysis is to estimate the stability of the results. When any single study was omitted, the pooled results showed a lack of change. This means that in the overall meta-analysis, no single study substantially affected the stability of the results. Therefore, the results of this meta-analysis were stable and reliable.

Publication bias
----------------

The publication bias of the included studies was investigated with the Begg's funnel plot and Egger's test. The results are presented in [Figures 7](#f7-idr-10-511){ref-type="fig"} and [8](#f8-idr-10-511){ref-type="fig"}. The shapes of the funnel plots showed some dissymmetry. Egger's test was used to provide statistical evidence of funnel plot symmetry, and there was no evidence of publication bias.

Discussion
==========

CMV is an opportunistic pathogenic microorganism that was discovered in immunocompetent individuals in the 1960s. As a β-herpesvirus, it is an important pathogen in many patients and widely exists in the majority of the population. After primary infection, the virus persists in the body and is located mainly in white blood cells and endothelial cells. CMV also has wide tissue tropism and is able to infect multiple organs, including the intestine.[@b36-idr-10-511] CMV was first found to be related with IBD in 1961.[@b37-idr-10-511] Since then, research on the effect of CMV infection on IBD activation has attracted broad attention and interest among clinicians. In IBD patients, immunosuppressive therapy, impaired absorption of nutrients, and dysfunction of the immune system render them susceptible to CMV infection.[@b38-idr-10-511] However, the role of CMV infection in patients with IBD is not confirmed yet. This meta-analysis sought to address unresolved debate regarding the relationship between CMV infection and IBD, especially CMV infection and steroid-resistant IBD.

When analyzing the relationship between CMV infection and IBD, our meta-analysis involved 19 studies including 1,218 patients and 972 healthy groups. Compared with the control groups, people exposed to HCMV infection had higher risk than those not exposed to CMV. Among 19 included studies, anti-CMV IgG, IgM, DNA, IE, and pp65 were used to detect CMV infection in IBD patients and healthy controls. Compared to the control groups, anti-CMV IE and pp65 were significantly higher in IBD patients, and the ORs of HCMV infection rate in IBD patients were, respectively, 8.43 \[95% CI =4.08--17.42, *p*\<0.00001\] and 7.44 \[95% CI =3.12--17.76, *p*\<0.00001\]. This suggested that CMV infection might be nearly 7\~8 times higher in IBD patients than in control groups, thereby indicating the association between IBD and CMV. Our results are in agreement with the previous reports[@b39-idr-10-511],[@b40-idr-10-511] suggesting that immunosuppressive medications might be an important risk factor for CMV infection. Significant heterogeneity of HCMV prevalence was noted when analyzed by ethnic subgroup. Our findings indicated that HCMV infection in Asia was the highest. Positive rates in Asian studies were 72.7% in the IBD population and 37.4% in the control population based on HCMV DNA tests, which might be the cause of the increased risk of IBD in the Asian population. However, there are limited included studies and insufficient participants in our research, so it needs further study in order to validate the relationship between ethnic difference and HCMV infection in IBD risk.

When analyzing the relationship between CMV infection and steroid resistance in IBD patients, our meta-analysis involved 17 studies including 1,306 IBD patients. Compared to CMV-negative groups, the OR in CMV-positive groups was 3.63 \[95% CI =1.99--6.62, *p*\<0.0001\], which suggested that CMV infection might cause an approximately fourfold risk of steroid resistance in IBD patients. When analyzed by ethnic subgrouping, the percentage of steroid-resistant patients in the CMV-positive groups was higher than in the CMV-negative groups regardless of the ethnicity. And when analyzed by CMV detection method, the percentage of steroid resistance in CMV-positive groups was also higher than that in CMV-negative groups for the majority of the CMV detection methods. These results thus showed a positive correlation between CMV infection and steroid resistance in IBD patients. Previous studies have also reported that local reactivation of CMV is closely related with severe and steroid-refractory IBD in patients.[@b3-idr-10-511],[@b41-idr-10-511],[@b42-idr-10-511]

Previous studies had linked CMV infection with IBD and its resistance to steroids; however, those researches failed to provide a strong and systematic relationship between CMV infection and IBD.[@b1-idr-10-511],[@b34-idr-10-511],[@b42-idr-10-511] In this research, we carried out a systematic meta-analysis assessing the effect of CMV infection on IBD and its resistance to steroids. Our results showed that there exists a significant association between CMV infection with IBD and its resistance to steroids. However, our study has several limitations. First, the number of articles included in this research is relatively small, ie, there were only 33 studies. Second, there have been some differences in the method of CMV detection and protocol, this may be because we only included published studies and did not include unpublished ones. An additional limitation in this research may be that there is a potential publication bias. In order to provide a more precise estimation on the basis of adjustment for confounders, more well-designed studies should be performed. Further prospective controlled trials will help to confirm these findings and identify subgroups of patients who might suffer from CMV infection.

In summary, our meta-analysis strongly suggests that CMV infection might be a probable cause of IBD and its resistance to steroids.
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![Forest plot (random-effect model) of the association between HCMV infection and IBD stratified by the study design based on HCMV IgG tests.\
**Abbreviations:** CI, confidence interval; HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; MH, Mantel--Haenszel; OR, odds ratio.](idr-10-511Fig2){#f2-idr-10-511}

![Forest plot (random-effect model) of the association between HCMV infection and IBD stratified by the study design based on HCMV IgM tests.\
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![Forest plot (random-effect model) of the association between HCMV infection and IBD stratified by the study design based on HCMV DNA tests.\
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![Forest plot (random-effect model) of the association between HCMV infection and IBD stratified by the study design based on HCMV IE tests.\
**Abbreviations:** CI, confidence interval; HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; IE, immediate-early; MH, Mantel--Haenszel; OR, odds ratio.](idr-10-511Fig5){#f5-idr-10-511}
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![Begg's funnel plot of the association between HCMV infection and IBD based on HCMV DNA tests.\
**Abbreviations:** HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; OR, odds ratio; SE, standard error of the mean.](idr-10-511Fig7){#f7-idr-10-511}

![Begg's funnel plot of the association between HCMV infection and steroid-resistant IBD.\
**Abbreviations:** HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; OR, odds ratio; SE, standard error of the mean.](idr-10-511Fig8){#f8-idr-10-511}

###### 

Main characteristics of the studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Source of cases              Study design type   Disease type      Definition of disease   Detection of HCMV   Case   Control          
  --------------------------------------------- ---------------------------- ------------------- ----------------- ----------------------- ------------------- ------ --------- ------ -----
  Rahbar et al,[@b8-idr-10-511] 2003            Sweden                       Case--control       UC and CD (IBD)   WHO                     DNA                 22     23        0      10

  Wakefiels et al,[@b10-idr-10-511] 1992        United Kingdom               Case--control       IBD               WHO                     DNA                 36     50        6      21

  Verdonk et al,[@b9-idr-10-511] 2006           The Netherlands              Case--control       IBD               WHO                     pp65                12     31        17     53

  Marszatek et al,[@b11-idr-10-511] 2011        Poland                       Case--control       IBD               WHO                     DNA\                13\    32        8\     15
                                                                                                                                           IgG\                9\               5\     
                                                                                                                                           IgM                 0                0      

  Nahar et al,[@b12-idr-10-511] 2015            Japan                        Case--control       UC                WHO                     DNA                 26     71        6      188

  Domenech et al,[@b13-idr-10-511] 2008         Spain                        Case--control       UC                WHO                     IgG                 66     94        19     25

  Sipponen et al,[@b14-idr-10-511] 2011         Finland                      Case--control       IBD               WHO                     pp65                64     79        6      15

  Knosel et al,[@b15-idr-10-511] 2009           Germany                      Case--control       CD                WHO                     DNA                 2      56        0      10

  Lavagna et al,[@b16-idr-10-511] 2006          Italy                        Case--control       UC                WHO                     IE\                 1\     24        0      20
                                                                                                                                           DNA                 3                       

  Dimitroulia et al,[@b17-idr-10-511] 2006      Greece                       Case--control       IBD               WHO                     pp65\               10\    85        0\     42
                                                                                                                                           DNA                 23               5      

  Van Kruiningen et al,[@b18-idr-10-511] 2007   USA                          Case--control       CD                WHO                     DNA                 1      70        1      41

  Kuwabara et al,[@b19-idr-10-511] 2007         Japan                        Case--control       IBD               WHO                     IE                  18     34        3      31

  Yi et al,[@b1-idr-10-511] 2013                People's Republic of China   Case--control       IBD               WHO                     DNA\                190\   226       173\   290
                                                                                                                                           IgG\                172\             147\   
                                                                                                                                           IgM                 4                1      

  Ciccocioppo et al,[@b20-idr-10-511] 2015      Italy                        Case--control       IBD               WHO                     IE                  9      40        2      40

  Ciccocioppo et al,[@b34-idr-10-511] 2016      Italy                        Case--control       IBD               WHO                     IE                  51     64        7      25

  Criscuoli et al,[@b21-idr-10-511] 2015        Italy                        Case--control       UC                WHO                     DNA\                11\    24        2\     24
                                                                                                                                           Pp65                8                2      

  Taherkhani et al,[@b22-idr-10-511] 2015       Iran                         Case--control       UC                WHO                     DNA                 12     98        0      67

  Thörn et al,[@b23-idr-10-511] 2016            Sweden                       Case--control       IBD               WHO                     IgM\                14\    67        1\     34
                                                                                                                                           DNA                 12               0      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CD, Crohn's disease; HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; IE, immediate-early; UC, ulcerative colitis; WHO, World Health Organization.

###### 

Main characteristics of the relationship between CMV infection and steroid-resistant IBD

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Source of cases   Study design type   Disease type   Definition of disease   Detection of HCMV   HCMV+   HCMV−        
  ------------------------------------------ ----------------- ------------------- -------------- ----------------------- ------------------- ------- ------- ---- -----
  Lévêque et al,[@b24-idr-10-511] 2010       France            Case                IBD            WHO                     DNA                 0       5       8    29

  Domènech et al,[@b13-idr-10-511] 2008      Spain             Case                UC             WHO                     IgG                 13      29      6    14

  Iida et al,[@b3-idr-10-511] 2013           Japan             Case                UC             WHO                     IgG\                62      141     20   46
                                                                                                                          IgM                                      

  Wada et al,[@b25-idr-10-511] 2003          Japan             Case                UC             WHO                     pp65                13      16      9    31

  Kambham et al,[@b26-idr-10-511] 2004       USA               Case                UC             WHO                     CMV inclusions\     12      13      28   67
                                                                                                                          IE                                       

  Maconi et al,[@b27-idr-10-511] 2005        Italy             Case                UC             WHO                     IE                  15      17      40   60

  Kuwabara et al,[@b19-idr-10-511] 2007      Japan             Case                IBD            WHO                     IE                  13      14      2    8

  Maher et al,[@b28-idr-10-511] 2009         Egypt             Case                IBD            WHO                     IgM\                8       9       15   63
                                                                                                                          IE                                       

  Criscuoli et al,[@b29-idr-10-511] 2011     Italy             Case                UC             WHO                     CMV inclusions\     6       28      11   57
                                                                                                                          IE\                                      
                                                                                                                          DNA\                                     
                                                                                                                          Pp65                                     

  Mccurdy et al,[@b30-idr-10-511] 2015       USA               Case                IBD            WHO                     CMV inclusions\     40      68      61   202
                                                                                                                          IE                                       

  Ciccocioppo et al,[@b20-idr-10-511] 2015   Italy             Case                IBD            WHO                     IE                  4       9       13   31

  Ciccocioppo et al,[@b34-idr-10-511] 2016   Italy             Case                IBD            WHO                     IE                  25      51      0    13

  Cottone et al,[@b31-idr-10-511] 2001       Italy             Case                IBD            WHO                     DNA                 7       7       12   55

  Criscuoli et al,[@b31-idr-10-511] 2004     Italy             Case                IBD            WHO                     pp65\               4       9       8    33
                                                                                                                          DNA                                      

  Criscuoli et al,[@b21-idr-10-511] 2015     Italy             Case                UC             WHO                     CMV inclusions\     5       11      7    13
                                                                                                                          IE\                                      
                                                                                                                          DNA\                                     
                                                                                                                          pp65                                     

  Kim et al,[@b35-idr-10-511] 2012           Korea             Case                UC             WHO                     DNA                 14      31      7    41

  Ormeci et al,[@b33-idr-10-511] 2016        Turkey            Case                IBD            WHO                     DNA                 8       13      5    72
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** HCMV, human cytomegalovirus; IBD, inflammatory bowel disease; IE, immediate-early; CMV, cytomegalovirus; UC, ulcerative colitis; WHO, World Health Organization.

###### 

Main characteristics of the studies included in the meta-analysis

  Characteristics                   Subgroup   N (Study)   N (Subject)   OR             95% CI           I2 (%)
  --------------------------------- ---------- ----------- ------------- -------------- ---------------- ----------------
  All ethnicity                                17          1,306         3.84           2.12--6.97       67
  Caucasian                         11         220         3.47          1.43--8.41     65               
  Asian                             4          140         4.75          1.16--19.52    80               
  Other                             2          141         5.43          1.22--24.17    55               
  CMV detection                     IgG        1           43            1.08           0.30--3.92       Not applicable
  DNA                               4          253         6.40          1.13--36.33    71               
  IE                                4          203         5.86          1.17--29.37    61               
  pp65                              1          47          10.59         2.42--46.33    Not applicable   
  CMV inclusion + IE                2          350         5.43          1.22--24.17    55               
  IgG + IgM                         1          187         1.02          0.52--2.00     Not applicable   
  IgM + IE                          1          72          25.60         2.96--221.58   Not applicable   
  pp65 + DNA                        1          42          2.50          0.54--11.63    Not applicable   
  CMV inclusion + IE + DNA + pp65   2          109         0.98          0.39--2.45     0                

**Abbreviations:** CI, confidence interval; CMV, cytomegalovirus; IE, immediate-early; OR, odds ratio.
